A robust and validated integrated prognostic index for defining risk groups in adult ALL: A EWALL collaborative study Blood Adv
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Mol Cancer Ther
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study) Ann Hematol
Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues Hum Genomics
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study Haematologica
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment CL LYMPH MYELOM LEUK
Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients BBA-MOL CELL RES
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA SCI REP-UK
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options Ann Hematol
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL